Previous close | 15.10 |
Open | 15.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 15.00 - 15.24 |
52-week range | 10.98 - 29.30 |
Volume | |
Avg. volume | 682 |
Market cap | 3.409M |
Beta (5Y monthly) | 1.10 |
PE ratio (TTM) | N/A |
EPS (TTM) | -5.14 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
WALTHAM, Mass., April 04, 2024--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 102,000 shares of the company’s common stock to th
WALTHAM, Mass., March 05, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11 at 2:00 p.m. ET.
Viridian Therapeutics ( NASDAQ:VRDN ) Full Year 2023 Results Key Financial Results Net loss: US$237.7m (loss widened by...